Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Non-Current Deffered Revenue (2017 - 2025)

Sutro Biopharma's Non-Current Deffered Revenue history spans 9 years, with the latest figure at $3.8 million for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue fell 79.12% year-over-year to $3.8 million; the TTM value through Sep 2025 reached $3.8 million, down 79.12%, while the annual FY2024 figure was $12.5 million, 76.52% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $3.8 million at Sutro Biopharma, down from $6.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $90.0 million in Q2 2022 and bottomed at $145000.0 in Q3 2021.
  • The 5-year median for Non-Current Deffered Revenue is $21.7 million (2024), against an average of $39.4 million.
  • The largest annual shift saw Non-Current Deffered Revenue tumbled 98.27% in 2021 before it surged 51439.31% in 2022.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $145000.0 in 2021, then soared by 61889.66% to $89.9 million in 2022, then tumbled by 40.61% to $53.4 million in 2023, then plummeted by 76.52% to $12.5 million in 2024, then plummeted by 70.02% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Non-Current Deffered Revenue are $3.8 million (Q3 2025), $6.9 million (Q2 2025), and $8.6 million (Q1 2025).